MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Alkermes plc Book Value 2011-2026 | ALKS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Alkermes plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.82 B | 1.46 B | 1.2 B | 1.04 B | 1.11 B | 1.07 B | 1.09 B | 1.17 B | 1.2 B | 1.21 B | 1.31 B | 1.4 B | 952 M | 854 M | 392 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.82 B | 392 M | 1.15 B |
Quarterly Book Value Alkermes plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.62 B | 1.51 B | 1.46 B | 1.29 B | 1.28 B | 1.25 B | 1.2 B | 1.36 B | 1.28 B | 1.01 B | 1.04 B | 1.04 B | - | 1.08 B | 1.11 B | 1.1 B | 1.1 B | 1.05 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 1.09 B | 1.09 B | 1.09 B | 1.09 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.21 B | 1.21 B | 1.21 B | 1.21 B | 1.31 B | 1.31 B | 1.31 B | 1.31 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 920 M | 885 M | 882 M | 854 M | 905 M | 910 M | - | 392 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 B | 392 M | 1.15 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-683 M | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
13.8 M | $ 0.91 | 2.42 % | $ 6.69 M | China |
 |
Edesa Biotech
EDSA
|
1.98 M | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Fortress Biotech
FBIO
|
62.2 M | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galectin Therapeutics
GALT
|
-126 M | $ 2.26 | 0.22 % | $ 144 M | USA |
 |
Galapagos NV
GLPG
|
3.24 B | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
870 M | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
27.1 M | $ 8.44 | - | $ 76.2 M | USA |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.95 | -1.77 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
23.2 M | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
5.17 B | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
12.1 M | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
23.5 M | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
1.64 B | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 104.54 | 2.92 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
-18.7 M | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-2.71 M | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
267 M | $ 1.43 | -4.03 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
319 M | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
18.6 M | $ 13.24 | 6.56 % | $ 1.75 B | Australia |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
830 M | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 3.22 | 7.69 % | $ 5.3 M | Israel |
 |
Liquidia Corporation
LQDA
|
44.7 M | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.08 | 0.74 % | $ 436 M | USA |